Previously, a single-arm, non-randomized feasibility study in HER2+ metastatic breast cancer patients (n = 20) was done using a HER2+ whole-cell breast cancer vaccine and weekly trastuzumab. The gene discussed is ERBB2; the disease is breast carcinoma.